Minuesa G, Albanese SK, Xie W, Kazansky Y, Worroll D, Chow A, Schurer A, Park S-M, Rotsides CZ, Taggart J et al..  2019.  Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia.. Nat Commun. 10(1):2691.

Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y et al..  2017.  Recurrent genetic defects on chromosome 5q in myeloid neoplasms.. Oncotarget. 8(4):6483-6495.

Liang H, Zheng Q-L, Fang P, Zhang J, Zhang T, Liu W, Guo M, Robinson CL, Chen S-B, Chen X-P et al..  2017.  Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells.. Sci Rep. 7:40361.

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G et al..  2016.  DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.. Nat Med. 22(12):1488-1495.

Goldberg AD, Tallman MS.  2016.  Down for the count in acute myeloid leukemia.. Blood. 128(18):2195-2197.

Taggart J, Ho T-C, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A et al..  2016.  MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.. Nat Commun. 7:10739.

Lin KH, Winter PS, Xie A, Roth C, Martz CA, Stein EM, Anderson GR, Tingley JP, Wood KC.  2016.  Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.. Sci Rep. 6:27696.

Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, Otto GA, Yelensky R, Hricik T, McKenney ASophia et al..  2014.  Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.. Proc Natl Acad Sci U S A. 111(50):E5401-10.

Brunner AM, Sadrzadeh H, Feng Y, Drapkin BJ, Ballen KK, Attar EC, Amrein PC, McAfee SL, Bin Chen Y-, Neuberg DS et al..  2013.  Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia.. Am J Hematol. 88(8):642-6.